Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine

Seizure

Volumn 22, Issue 7, 2013, Pages 528-536

  Zaccara, Gaetano ^a   Giovannelli, Fabio ^a   Maratea, Dario ^b   Fadda, Valeria ^b   Verrotti, Alberto ^c  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b Laboratorio SIFO di Farmacoeconomia   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Adverse events; Antiepileptic drugs; Epilepsy; Eslicarbazepine; Lacosamide; Oxcarbazepine

Indexed keywords

ANTICONVULSIVE AGENT; ESLICARBAZEPINE ACETATE; HARKOSERIDE; OXCARBAZEPINE; PLACEBO;

ADJUVANT THERAPY; ARTICLE; ATAXIA; ATTRIBUTABLE RISK; CONTROLLED STUDY; COORDINATION DISORDER; DIPLOPIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; EXPERIMENTAL THERAPY; FATIGUE; HEADACHE; HUMAN; META ANALYSIS; MONOTHERAPY; NAUSEA; NEUROLOGICAL COMPLICATION; NYSTAGMUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOMNOLENCE; TREATMENT WITHDRAWAL; TREMOR; VERTIGO; VOMITING;

EID: 84881175373     PISSN: 10591311     EISSN: 15322688     Source Type: Journal    
DOI: 10.1016/j.seizure.2013.03.016     Document Type: Article

References (38)

1. E. Beghi, and R. Di Mascio Antiepileptic drug toxicity: definition and mechanism of action Italian Journal of Neurological Sciences 7 2 1986 209 222
2. R. Guerrini, G. Zaccara, G. la Marca, and A. Rosati Safety and tolerability of antiepileptic drug treatment in children with epilepsy Drug Safety 35 7 2012 519 533
3. G. Zaccara, M. Cincotta, A. Borgheresi, and F. Balestrieri Adverse motor effects induced by antiepileptic drugs Epileptic Disorders 6 2004 153 168
4. J.I. Sirven, T.D. Fife, D.M. Wingerchuk, and J.F. Drazkowski Second-generation antiepileptic drugs' impact on balance: a meta-analysis Mayo Clinic Proceedings 82 1 2007 40 47
5. G. Zaccara, P. Perucca, G. Loiacono, F. Giovannelli, and A. Verrotti The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials Epilepsia July 2012 10.1111/j.1528-1167.2012.03589. x
6. L.J. Stephen, K. Kelly, P. Parker, and M.J. Brodie Adjunctive lacosamide in clinical practice: sodium blockade with a difference? Epilepsy Behavior 22 3 2011 499 504
7. U. Specht, T.W. May, M. Rohde, V. Wagner, R.C. Schmidt, and M. Schutz Cerebellar atrophy decreases the threshold of carbamazepine toxicity in patients with chronic focal epilepsy Archives of Neurology 54 1997 427 431
8. G. Zaccara, P. Gangemi, P. Perucca, and L. Specchio The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials Epilepsia 52 4 2011 826 836
9. Medicines and Healthcare products Regulatory Agency. Oxcarbazepine tablets: summary of product characteristics [online]. http://www.mhra.gov.uk/ home/groups/par/documents/websiteresources/con052082.pdf [accessed 03.09.2012].
10. ® (oxcarbazepine tablets). US prescribing information [online]. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/021014s015s019s022s024s025s027s028, 021285s009s013s015s018s019s020s022lbl.pdf [accessed 03.09.2012].
11. ® (eslicarbazepine acetate tablets): summary of product characteristics [online]. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000988/WC500047225.pdf [accessed 03.09.2012].
12. ® (lacosamide tablets): summary of product characteristics [online]. http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000863/WC500050338.pdf [accessed 03.09.2012].
13. ® (lacosamide tablets). US prescribing information [online]. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/022255lbl.pdf [accessed 03.09.2012].
14. D. Lozsadi, K. Hemming, and A.G. Marson Pregabalin add-on for drug-resistant partial epilepsy Cochrane Database of Systematic Reviews July 1 2008 CD005612
15. RevMan Review manager (RevMan) [Computer program]. Version 5.1. The Nordic Cochrane Centre 2011 The Cochrane Collaboration Copenhagen
16. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials Journal of Clinical Epidemiology 50 1997 683 691
17. V. Fadda, D. Maratea, S. Trippoli, and A. Messori Network meta-analysis. Results can be summarised in a simple figure British Medical Journal 342 2011 10.1136/bmj.d1555
18. E. Ben-Menachem, A.A. Gabbai, A. Hufnagel, J. Maia, L. Almeida, and P. Soares-da-Silva Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy Epilepsy Research 89 2-3 2010 278 285
19. C. Elger, M. Bialer, J.A. Cramer, J. Maia, L. Almeida, and P. Soares-da-Silva Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures Epilepsia 48 3 2007 497 504
20. C. Elger, P. Halász, J. Maia, L. Almeida, and P. Soares-da-Silva BIA-2093-301 investigators study group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study Epilepsia 50 3 2009 454 463
21. A. Gil-Nagel, J. Lopes-Lima, L. Almeida, J. Maia, and P. Soares-da-Silva BIA-2093-303 investigators study group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures Acta Neurologica Scandinavica 120 5 2009 281 287
22. E. Ben-Menachem, V. Biton, D. Jatuzis, B. Abou-Khalil, P. Doty, and G.D. Rudd Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures Epilepsia 48 7 2007 1308 1317
23. S. Chung, M.R. Sperling, V. Biton, G. Krauss, D. Hebert, and G.D. Rudd SP754 study group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial Epilepsia 51 6 2010 958 967
24. P. Halász, R. Kälviäinen, M. Mazurkiewicz- Beldzińska, F. Rosenow, P. Doty, and D. Hebert SP755 study group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial Epilepsia 50 3 2009 443 453
25. G. Barcs, E.B. Walker, C.E. Elger, A. Scaramelli, H. Stefan, and Y. Sturm Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy Epilepsia 41 12 2000 1597 1607
26. J. Costa, F. Fareleira, R. Ascenção, M. Borges, C. Sampaio, and A. Vaz-Carneiro Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis Epilepsia 52 7 2011 1280 1291
27. L. Gao, L. Xia, F.L. Zhao, and Li SC Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials Epilepsy Research 2012 http://dx.doi.org/10.1016/j.eplepsyres.2012.06.005
28. M. Martyn-St James, J. Glanville, R. McCool, S. Duffy, J. Cooper, and P. Hugel The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison Seizure 21 9 2012 665 678
29. T. Nunes, J.F. Rocha, A. Falcão, L. Almeida, and P. Soares-da-Silva Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers Epilepsia July 2012 10.1111/j.1528-1167.2012.03595.x
30. A.C. Errington, T. Sto, C. Heers, and G. Lees The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels Molecular Pharmacology 73 2008 157 169
31. J. Benes, A. Parada, A.A. Figueiredo, P.C. Alves, A.P. Freitas, and D.A. Learmonth Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5Hdibenz[b,f]azepine-5-carboxamide derivatives Journal of Medicinal Chemistry 42 14 1999 2582 2587
32. M.E. Brown, and R.S. El-Mallakh Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures Therapeutics and Clinical Risk Management 6 2010 103 109
33. L. Tothfalusi, S. Speidl, and L. Endrenyi Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets British Journal of Clinical Pharmacology 65 1 2008 110 122
34. R. Canger, A.C. Altamura, O. Belvedere, F. Monaco, G.C. Monza, and G.C. Muscas Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study Acta Neurologica Scandinavica 82 1 1990 9 13
35. S. Striano, P. Striano, P. Di Nocera, D. Italiano, C. Fasiello, and P. Ruosi Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy Epilepsy Research 69 2 2006 170 176
36. E. Perucca, C. Elger, P. Halász, A. Falcão, L. Almeida, and P. Soares-da-Silva Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures Epilepsy Research 96 1/2 2011 132 139
37. E. Faught Oxcarbazepine S.D. Shorvon, E. Perucca, D.R. Fish, W.E. Dodson, The treatment of epilepsy 2nd edition 2005 Blackwell Publishing Oxford 451 460
38. S. Rheims, E. Perucca, M. Cucherat, and P. Ryvlin Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis Epilepsia 52 2 2011 219 233